You are here

Creating Immunostimulatory Dendritic Cells From iPSCs

The directed differentiation of induced pluripotent stem cells (iPSCs) provides a scalable means to generate therapeutically relevant numbers of dendritic cells (DCs); however, as with many iPSC-derived cell types, iPSC-DCs do not reach full functional maturity and display limited immunogenicity. Researchers from the lab of Paul J. Fairchild (University of Oxford, UK) may have solved this problem in their recent STEM CELLS study, in which Horton et al. exploit the “epigenetic memory” of DC origin through the reprogramming of existing DCs into iPSCs to provide a large number of “DC-primed” pluripotent cells for the differentiation of large amounts of mature DCs with an immunostimulatory activity suitable for use in immunotherapy.